text:
Recent Development on Anti-Obesity Compounds and their Mechanisms of Action: A Review
Author(s): Yixing Qiu, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China	Huanghe Yu, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China	Rong Zeng, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China	Shiyin Guo, College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, Hunan, China	Muhammad Daniyal, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China	Zeyu Deng, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China	Aibing Wang*, The Key Laboratory of Animal Vaccine & Protein Engineering, College of Veterinary Medicine, Hunan Agricultural University, Changsha 410128, Hunan, China	Wei Wang*	TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China
Journal Name: Current Medicinal Chemistry
Volume 27 , Issue 21 , 2020
DOI : 10.2174/0929867326666190215114359
Translate in Chinese
Obesity, associated with a series of complications such as diabetes, hypertension, and heart disease, is a great threat to human health and leads to increased morbidity and mortality. Despite the presence of anti-obesity agents on the market, the application of these drugs is limited because of their typical side effects. More effective and safe weight-loss drugs are being pursued by many researchers, correspondingly, growing small molecules and natural products with anti-obesity effects have been identified and the molecular mechanisms underlying the action of the novel and known compounds have at least partially been revealed. Therefore, the field does witness great progress year by year. In this review, we intend to provide a comprehensive and updated view on the known and novel compounds which possess anti-obesity effects and further classify them according to the molecular mechanisms of their actions in regulating the major anti-obesity pathways.
Keywords: Obesity, active compounds, mechanisms of action, lipid metabolism and energy expenditure, adipocyte differentiation, insulin resistance, chronic inflammation, gut microorganism.
Skinner, A.C.; Ravanbakht, S.N.; Skelton, J.A.; Perrin, E.M.; Armstrong, S.C. Prevalence of obesity and severe obesity in US children, 1999-2016. Pediatrics, 2018, 141(3), e20173459
[http://dx.doi.org/10.1542/peds.2017-3459] [PMID: 29483202]
Hales, C.M.; Carroll, M.D.; Fryar, C.D.; Ogden, C.L. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief, 2017, (288), 1-8.
[PMID: 29155689]
Lobstein, T.; Jackson-Leach, R.; Moodie, M.L.; Hall, K.D.; Gortmaker, S.L.; Swinburn, B.A.; James, W.P.T.; Wang, Y.; McPherson, K. Child and adolescent obesity: part of a bigger picture. Lancet, 2015, 385(9986), 2510-2520.
[http://dx.doi.org/10.1016/S0140-6736(14)61746-3] [PMID: 25703114]
Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F.; Abraham, J.P.; Abu-Rmeileh, N.M.; Achoki, T.; AlBuhairan, F.S.; Alemu, Z.A.; Alfonso, R.; Ali, M.K.; Ali, R.; Guzman, N.A.; Ammar, W.; Anwari, P.; Banerjee, A.; Barquera, S.; Basu, S.; Bennett, D.A.; Bhutta, Z.; Blore, J.; Cabral, N.; Nonato, I.C.; Chang, J.C.; Chowdhury, R.; Courville, K.J.; Criqui, M.H.; Cundiff, D.K.; Dabhadkar, K.C.; Dandona, L.; Davis, A.; Dayama, A.; Dharmaratne, S.D.; Ding, E.L.; Durrani, A.M.; Esteghamati, A.; Farzadfar, F.; Fay, D.F.; Feigin, V.L.; Flaxman, A.; Forouzanfar, M.H.; Goto, A.; Green, M.A.; Gupta, R.; Hafezi-Nejad, N.; Hankey, G.J.; Harewood, H.C.; Havmoeller, R.; Hay, S.; Hernandez, L.; Husseini, A.; Idrisov, B.T.; Ikeda, N.; Islami, F.; Jahangir, E.; Jassal, S.K.; Jee, S.H.; Jeffreys, M.; Jonas, J.B.; Kabagambe, E.K.; Khalifa, S.E.; Kengne, A.P.; Khader, Y.S.; Khang, Y.H.; Kim, D.; Kimokoti, R.W.; Kinge, J.M.; Kokubo, Y.; Kosen, S.; Kwan, G.; Lai, T.; Leinsalu, M.; Li, Y.; Liang, X.; Liu, S.; Logroscino, G.; Lotufo, P.A.; Lu, Y.; Ma, J.; Mainoo, N.K.; Mensah, G.A.; Merriman, T.R.; Mokdad, A.H.; Moschandreas, J.; Naghavi, M.; Naheed, A.; Nand, D.; Narayan, K.M.; Nelson, E.L.; Neuhouser, M.L.; Nisar, M.I.; Ohkubo, T.; Oti, S.O.; Pedroza, A.; Prabhakaran, D.; Roy, N.; Sampson, U.; Seo, H.; Sepanlou, S.G.; Shibuya, K.; Shiri, R.; Shiue, I.; Singh, G.M.; Singh, J.A.; Skirbekk, V.; Stapelberg, N.J.; Sturua, L.; Sykes, B.L.; Tobias, M.; Tran, B.X.; Trasande, L.; Toyoshima, H.; van de Vijver, S.; Vasankari, T.J.; Veerman, J.L.; Velasquez-Melendez, G.; Vlassov, V.V.; Vollset, S.E.; Vos, T.; Wang, C.; Wang, X.; Weiderpass, E.; Werdecker, A.; Wright, J.L.; Yang, Y.C.; Yatsuya, H.; Yoon, J.; Yoon, S.J.; Zhao, Y.; Zhou, M.; Zhu, S.; Lopez, A.D.; Murray, C.J.; Gakidou, E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014, 384(9945), 766-781.
Popkin, B.M.; Adair, L.S.; Ng, S.W. Global nutrition transition and the pandemic of obesity in developing countries. Nutr. Rev., 2012, 70(1), 3-21.
[http://dx.doi.org/10.1111/j.1753-4887.2011.00456.x] [PMID: 22221213]
Poobalan, A.; Aucott, L. Obesity among young adults in developing countries: a systematic overview. Curr. Obes. Rep., 2016, 5(1), 2-13.
[http://dx.doi.org/10.1007/s13679-016-0187-x] [PMID: 26883372]
Jia, P.; Xue, H.; Zhang, J.; Wang, Y. Time trend and demographic and geographic disparities in child-hood obesity prevalence in china-evidence from twenty years of longitudinal data. Int. J. Environ. Res. Public Health, 2017, 14(4), 369.
[http://dx.doi.org/10.3390/ijerph14040369] [PMID: 28362361]
Zhang, J.; Wang, H.; Wang, Z.; Du, W.; Su, C.; Zhang, J.; Jiang, H.; Jia, X.; Huang, F.; Ouyang, Y.; Wang, Y.; Zhang, B. Prevalence and stabilizing trends in overweight and obesity among children and adolescents in China, 2011-2015. BMC Public Health, 2018, 18(1), 571.
[http://dx.doi.org/10.1186/s12889-018-5483-9] [PMID: 29716560]
Witkamp, R.F. 3.15-Biologically active compounds in food products and their effects on obesity and diabetes. Comprehensive Natural Products II, 2010, 46(1), 509-545.
[http://dx.doi.org/10.1016/B978-008045382-8.00063-0]
Kumar, R.B.; Aronne, L.J. Review of multimodal therapies for obesity treatment: Including dietary, counseling strategies, and pharmacologic interventions. Tech. Gastrointest. Endosc., 2017, 19(1), 12-17.
[http://dx.doi.org/10.1016/j.tgie.2016.11.003]
Tilg, H.; Hotamisligil, G.S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology, 2006, 131(3), 934-945.
[http://dx.doi.org/10.1053/j.gastro.2006.05.054] [PMID: 16952562]
Zhang, W.L.; Zhu, L.; Jiang, J.G. Active ingredients from natural botanicals in the treatment of obesity. Obes. Rev., 2014, 15(12), 957-967.
[http://dx.doi.org/10.1111/obr.12228] [PMID: 25417736]
Martel, J.; Ojcius, D.M.; Chang, C-J.; Lin, C-S.; Lu, C-C.; Ko, Y-F.; Tseng, S-F.; Lai, H-C.; Young, J.D. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat. Rev. Endocrinol., 2017, 13(3), 149-160.
[http://dx.doi.org/10.1038/nrendo.2016.142] [PMID: 27636731]
Yun, J.W. Possible anti-obesity therapeutics from nature--a review. Phytochemistry, 2010, 71(14-15), 1625-1641.
[http://dx.doi.org/10.1016/j.phytochem.2010.07.011] [PMID: 20732701]
Sinha, R. Role of addiction and stress neurobiology on food intake and obesity. Biol. Psychol., 2018, 131, 5-13.
[http://dx.doi.org/10.1016/j.biopsycho.2017.05.001] [PMID: 28479142]
Redman, L.M.; Ravussin, E. Lorcaserin for the treatment of obesity. Drugs Today (Barc), 2010, 46(12), 901-910.
[http://dx.doi.org/10.1358/dot.2010.46.12.1556433] [PMID: 21589947]
Heal, D.J.; Smith, S.L.; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther., 2008, 117(2), 207-231.
[http://dx.doi.org/10.1016/j.pharmthera.2007.08.006] [PMID: 18068807]
Thomsen, W.J.; Grottick, A.J.; Menzaghi, F.; Reyes-Saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; Al-Shamma, H.; Smith, B.; Chalmers, D.; Behan, D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther., 2008, 325(2), 577-587.
[http://dx.doi.org/10.1124/jpet.107.133348] [PMID: 18252809]
Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med., 2010, 363(3), 245-256.
[http://dx.doi.org/10.1056/NEJMoa0909809] [PMID: 20647200]
Smith, S.R.; Prosser, W.A.; Donahue, D.J.; Morgan, M.E.; Anderson, C.M.; Shanahan, W.R. APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring), 2009, 17(3), 494-503.
[http://dx.doi.org/10.1038/oby.2008.537] [PMID: 19057523]
Martin, C.K.; Redman, L.M.; Zhang, J.; Sanchez, M.; Anderson, C.M.; Smith, S.R.; Ravussin, E. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J. Clin. Endocrinol. Metab., 2011, 96(3), 837-845.
[http://dx.doi.org/10.1210/jc.2010-1848] [PMID: 21190985]
Yang, H.Y.; Tae, J.; Seo, Y.W.; Kim, Y.J.; Im, H.Y.; Choi, G.D.; Cho, H.; Park, W.K.; Kwon, O.S.; Cho, Y.S.; Ko, M.; Jang, H.; Lee, J.; Choi, K.; Kim, C.H.; Lee, J.; Pae, A.N. Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity. Eur. J. Med. Chem., 2013, 63(5), 558-569.
[http://dx.doi.org/10.1016/j.ejmech.2013.02.020] [PMID: 23537943]
Wren, A.M.; Seal, L.J.; Cohen, M.A.; Brynes, A.E.; Frost, G.S.; Murphy, K.G.; Dhillo, W.S.; Ghatei, M.A.; Bloom, S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab., 2001, 86(12), 5992.
[http://dx.doi.org/10.1210/jcem.86.12.8111] [PMID: 11739476]
Takahashi, B.; Funami, H.; Iwaki, T.; Maruoka, H.; Shibata, M.; Koyama, M.; Nagahira, A.; Kamiide, Y.; Kanki, S.; Igawa, Y.; Muto, T. Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model. Bioorg. Med. Chem., 2015, 23(15), 4792-4803.
[http://dx.doi.org/10.1016/j.bmc.2015.05.047] [PMID: 26100441]
Kroog, G.S.; Jensen, R.T.; Battey, J.F. Mammalian bombesin receptors. Med. Res. Rev., 1995, 15(5), 389-417.
[http://dx.doi.org/10.1002/med.2610150502] [PMID: 8531502]
Guan, X.M.; Chen, H.; Dobbelaar, P.H.; Dong, Y.; Fong, T.M.; Gagen, K.; Gorski, J.; He, S.; Howard, A.D.; Jian, T.; Jiang, M.; Kan, Y.; Kelly, T.M.; Kosinski, J.; Lin, L.S.; Liu, J.; Marsh, D.J.; Metzger, J.M.; Miller, R.; Nargund, R.P.; Palyha, O.; Shearman, L.; Shen, Z.; Stearns, R.; Strack, A.M.; Stribling, S.; Tang, Y.S.; Wang, S.P.; White, A.; Yu, H.; Reitman, M.L. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab., 2010, 11(2), 101-112.
[http://dx.doi.org/10.1016/j.cmet.2009.12.008] [PMID: 20096642]
Ohki-Hamazaki, H.; Watase, K.; Yamamoto, K.; Ogura, H.; Yamano, M.; Yamada, K.; Maeno, H.; Imaki, J.; Kikuyama, S.; Wada, E.; Wada, K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature, 1997, 390(6656), 165-169.
[http://dx.doi.org/10.1038/36568] [PMID: 9367152]
Chobanian, H.R.; Guo, Y.; Liu, P.; Chioda, M.; Lanza, T.J., Jr; Chang, L.; Kelly, T.M.; Kan, Y.; Palyha, O.; Guan, X.M.; Marsh, D.J.; Metzger, J.M.; Gorski, J.N.; Raustad, K.; Wang, S.P.; Strack, A.M.; Miller, R.; Pang, J.; Madeira, M.; Lyons, K.; Dragovic, J.; Reitman, M.L.; Nargund, R.P.; Lin, L.S. Discovery of MK-7725, A potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity. ACS Med. Chem. Lett., 2012, 3(3), 252-256.
[http://dx.doi.org/10.1021/ml200304j] [PMID: 24900461]
Liu, J.; He, S.; Jian, T.; Dobbelaar, P.H.; Sebhat, I.K.; Lin, L.S.; Goodman, A.; Guo, C.; Guzzo, P.R.; Hadden, M.; Henderson, A.J.; Pattamana, K.; Ruenz, M.; Sargent, B.J.; Swenson, B.; Yet, L.; Tamvakopoulos, C.; Peng, Q.; Pan, J.; Kan, Y.; Palyha, O.; Kelly, T.M.; Guan, X.M.; Howard, A.D.; Marsh, D.J.; Metzger, J.M.; Reitman, M.L.; Wyvratt, M.J.; Nargund, R.P. Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorg. Med. Chem. Lett., 2010, 20(7), 2074-2077.
[http://dx.doi.org/10.1016/j.bmcl.2010.02.076] [PMID: 20219372]
Kowalski, T.J.; McBriar, M.D. Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs, 2004, 13(9), 1113-1122.
[http://dx.doi.org/10.1517/13543784.13.9.1113] [PMID: 15330743]
Ludwig, D.S.; Tritos, N.A.; Mastaitis, J.W.; Kulkarni, R.; Kokkotou, E.; Elmquist, J.; Lowell, B.; Flier, J.S.; Maratos-Flier, E. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest., 2001, 107(3), 379-386.
[http://dx.doi.org/10.1172/JCI10660] [PMID: 11160162]
Mihalic, J.T.; Chen, X.; Fan, P.; Chen, X.; Fu, Y.; Liang, L.; Reed, M.; Tang, L.; Chen, J.L.; Jaen, J.; Li, L.; Dai, K. Discovery of a novel series of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett., 2011, 21(23), 7001-7005.
Schober, G.; Arnold, M.; Birtles, S.; Buckett, L.K.; Pacheco-López, G.; Turnbull, A.V.; Langhans, W.; Mansouri, A. Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats. J. Lipid Res., 2013, 54(5), 1369-1384.
[http://dx.doi.org/10.1194/jlr.M035154] [PMID: 23449193]
Qian, Y.; Wertheimer, S.J.; Ahmad, M.; Cheung, A.W-H.; Firooznia, F.; Hamilton, M.M.; Hayden, S.; Li, S.; Marcopulos, N.; McDermott, L.; Tan, J.; Yun, W.; Guo, L.; Pamidimukkala, A.; Chen, Y.; Huang, K.S.; Ramsey, G.B.; Whittard, T.; Conde-Knape, K.; Taub, R.; Rondinone, C.M.; Tilley, J.; Bolin, D. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. J. Med. Chem., 2011, 54(7), 2433-2446.
[http://dx.doi.org/10.1021/jm101580m] [PMID: 21413799]
Schober, G.; Arnold, M.; Birtles, S.; Buckett, L.; Turnbull, A.V.; Langhans, W. Diacylglycerol acyl-transferase-1 (DGAT-1) inhibition reduces food intake and blunts postprandial increases in circulating fat metabolites in high fat diet (HFD)-fed rats. Appetite, 2010, 54(3), 674-674.
[http://dx.doi.org/10.1016/j.appet.2010.04.180]
Saely, C.H.; Geiger, K.; Drexel, H. Brown versus white adipose tissue: a mini-review. Gerontology, 2012, 58(1), 15-23.
[http://dx.doi.org/10.1159/000321319] [PMID: 21135534]
Enerbäck, S. Brown adipose tissue in humans. Int. J. Obes., 2010, 34(Suppl. 1), S43-S46.
[http://dx.doi.org/10.1038/ijo.2010.183] [PMID: 20935666]
Fujioka, S.; Matsuzawa, Y.; Tokunaga, K.; Tarui, S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism, 1987, 36(1), 54-59.
[http://dx.doi.org/10.1016/0026-0495(87)90063-1] [PMID: 3796297]
Solini, A.; Bonora, E.; Bonadonna, R.; Castellino, P.; DeFronzo, R.A. Protein metabolism in human obesity: relationship with glucose and lipid metabolism and with visceral adipose tissue. J. Clin. Endocrinol. Metab., 1997, 82(8), 2552-2558.
[http://dx.doi.org/10.1210/jc.82.8.2552] [PMID: 9253333]
Yamamoto, T.; Yamaguchi, H.; Miki, H.; Kitamura, S.; Nakada, Y.; Aicher, T.D.; Pratt, S.A.; Kato, K. A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. Eur. J. Pharmacol., 2011, 650(2-3), 663-672.
[http://dx.doi.org/10.1016/j.ejphar.2010.10.040] [PMID: 21034741]
Yamamoto, T.; Yamaguchi, H.; Miki, H.; Shimada, M.; Nakada, Y.; Ogino, M.; Asano, K.; Aoki, K.; Tamura, N.; Masago, M.; Kato, K. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. Eur. J. Pharmacol., 2010, 640(1-3), 243-249.
Fox, B.M.; Furukawa, N.; Hao, X.; Iio, K.; Inaba, T.; Jackson, S.M.; Kayser, F.; Labelle, M.; Li, K.; Matsui, T. Fused bicyclic nitrogen-containing heterocycles; Google Patents, 2007.
Tsuda, N.; Kumadaki, S.; Higashi, C.; Ozawa, M.; Shinozaki, M.; Kato, Y.; Hoshida, K.; Kikuchi, S.; Nakano, Y.; Ogawa, Y.; Furusako, S. Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice. PLoS One, 2014, 9(11), e112027-e112027.
[http://dx.doi.org/10.1371/journal.pone.0112027] [PMID: 25405858]
Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
Girroir, E.E.; Hollingshead, H.E.; He, P.; Zhu, B.; Perdew, G.H.; Peters, J.M. Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem. Biophys. Res. Commun., 2008, 371(3), 456-461.
[http://dx.doi.org/10.1016/j.bbrc.2008.04.086] [PMID: 18442472]
Braissant, O.; Foufelle, F.; Scotto, C.; Dauça, M.; Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, 137(1), 354-366.
[http://dx.doi.org/10.1210/endo.137.1.8536636] [PMID: 8536636]
Szkudelska, K.; Szkudelski, T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol., 2010, 635(1-3), 1-8.
Szkudelski, T.; Szkudelska, K. Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215(1), 34-39.
Aguirre, L.; Fernández-Quintela, A.; Arias, N.; Portillo, M.P. Resveratrol: anti-obesity mechanisms of action. Molecules, 2014, 19(11), 18632-18655.
[http://dx.doi.org/10.3390/molecules191118632] [PMID: 25405284]
Lasa, A.; Churruca, I.; Eseberri, I.; Andrés-Lacueva, C.; Portillo, M.P. Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol. Nutr. Food Res., 2012, 56(10), 1559-1568.
[http://dx.doi.org/10.1002/mnfr.201100772] [PMID: 22945685]
Fernández-Quintela, A.; Carpéné, C.; Fernández, M.; Aguirre, L.; Milton-Laskibar, I.; Contreras, J.; Portillo, M.P. Anti-obesity effects of resveratrol: comparison between animal models and humans. J. Physiol. Biochem., 2016, 73(3), 417-429.
[http://dx.doi.org/10.1007/s13105-016-0544-y] [PMID: 27981508]
Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R.H.; van de Weijer, T.; Goossens, G.H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; Moonen-Kornips, E.; Hesselink, M.K.C.; Kunz, I.; Schrauwen-Hinderling, V.B.; Blaak, E.; Auwerx, J.; Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab., 2011, 14(5), 612-622.
Ghadieh, H.E.; Smiley, Z.N.; Kopfman, M.W.; Najjar, M.G.; Hake, M.J.; Najjar, S.M. Chlorogenic acid/chromium supplement rescues diet-induced insulin resistance and obesity in mice. Nutr. Metab. (Lond.), 2015, 12(1), 19.
Cho, A-S.; Jeon, S-M.; Kim, M-J.; Yeo, J.; Seo, K-I.; Choi, M-S.; Lee, M-K. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem. Toxicol., 2010, 48(3), 937-943.
[http://dx.doi.org/10.1016/j.fct.2010.01.003] [PMID: 20064576]
Diamant, M.; Heine, R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 2003, 63(13), 1373-1405.
[http://dx.doi.org/10.2165/00003495-200363130-00004] [PMID: 12825962]
Saltiel, A.R.; Olefsky, J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 1996, 45(12), 1661-1669.
[http://dx.doi.org/10.2337/diab.45.12.1661] [PMID: 8922349]
Bhattarai, B.R.; Kafle, B.; Hwang, J-S.; Ham, S.W.; Lee, K-H.; Park, H.; Han, I-O.; Cho, H. Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-γ activators. Bioorg. Med. Chem. Lett., 2010, 20(22), 6758-6763.
Tercel, M.; Marnane, R.N.; Tatnell, M.A.; Stevenson, R.J.; Halim, A.; Lu, G.L.; Duchesnes, C.; Truong, M.; Denny, W.A.; Wilson, W.R.; Mountjoy, K.G. An indoline-derived compound that markedly reduces mouse body weight. Int. J. Obes., 2013, 37(5), 685-692.
[http://dx.doi.org/10.1038/ijo.2012.97] [PMID: 22732909]
Shimano, H.; Yahagi, N.; Amemiya-Kudo, M.; Hasty, A.H.; Osuga, J.; Tamura, Y.; Shionoiri, F.; Iizuka, Y.; Ohashi, K.; Harada, K.; Gotoda, T.; Ishibashi, S.; Yamada, N. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem., 1999, 274(50), 35832-35839.
[http://dx.doi.org/10.1074/jbc.274.50.35832] [PMID: 10585467]
Shimano, H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog. Lipid Res., 2001, 40(6), 439-452.
Zhao, X.; Xiaoli, ; Zong, H.; Abdulla, A.; Yang, E.S.; Wang, Q.; Ji, J.Y.; Pessin, J.E.; Das, B.C.; Yang, F. Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. Diabetes, 2014, 63(7), 2464-2473.
[http://dx.doi.org/10.2337/db13-0835] [PMID: 24608444]
Kim, D.D.; Krishnarajah, J.; Lillioja, S.; de Looze, F.; Marjason, J.; Proietto, J.; Shakib, S.; Stuckey, B.G.A.; Vath, J.E.; Hughes, T.E. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes. Metab., 2015, 17(6), 566-572.
[http://dx.doi.org/10.1111/dom.12457] [PMID: 25732625]
Hughes, T.E.; Kim, D.D.; Marjason, J.; Proietto, J.; Whitehead, J.P.; Vath, J.E. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring), 2013, 21(9), 1782-1788.
[http://dx.doi.org/10.1002/oby.20356] [PMID: 23512440]
Rupnick, M.A.; Panigrahy, D.; Zhang, C.Y.; Dallabrida, S.M.; Lowell, B.B.; Langer, R.; Folkman, M.J. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10730-10735.
[http://dx.doi.org/10.1073/pnas.162349799] [PMID: 12149466]
Lee, S.; Yang, W.K.; Song, J.H.; Ra, Y.M.; Jeong, J.H.; Choe, W.; Kang, I.; Kim, S.S.; Ha, J. Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3. Biochem. Pharmacol., 2013, 85(7), 965-976.
[http://dx.doi.org/10.1016/j.bcp.2012.12.023] [PMID: 23337568]
Shi, L.; Wang, J.; Wang, Y.; Feng, Y. MDG-1, an Ophiopogon polysaccharide, alleviates hyperlipidemia in mice based on metabolic profile of bile acids. Carbohydr. Polym., 2016, 150, 74-81.
[http://dx.doi.org/10.1016/j.carbpol.2016.05.008] [PMID: 27312615]
Edwards, P.A.; Kast, H.R.; Anisfeld, A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res., 2002, 43(1), 2-12.
Calkin, A.C.; Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol., 2012, 13(4), 213-224.
[http://dx.doi.org/10.1038/nrm3312] [PMID: 22414897]
Souza, G.A.; Ebaid, G.X.; Seiva, F.R.; Rocha, K.H.; Galhardi, C.M.; Mani, F.; Novelli, E.L. N-acetylcysteine an allium plant compound improves high-sucrose diet-induced obesity and related effects. Evid. Based Complement. Alternat. Med., 2011, 2011, 643269
[http://dx.doi.org/10.1093/ecam/nen070] [PMID: 19001480]
Mela, D.J.; Rogers, P.J. Energy intake and expenditure: basic concepts and issues; Springer: US, 1998.
Bonet, M.L.; Oliver, P.; Palou, A. Pharmacological and nutritional agents promoting browning of white adipose tissue. Biochim. Biophys. Acta, 2013, 1831(5), 969-985.
[http://dx.doi.org/10.1016/j.bbalip.2012.12.002] [PMID: 23246573]
Ricquier, D.; Bouillaud, F. Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. J. Physiol., 2000, 529(Pt 1), 3-10.
Brand, M.D.; Esteves, T.C. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab., 2005, 2(2), 85-93.
Maeda, H.; Hosokawa, M.; Sashima, T.; Murakami-Funayama, K.; Miyashita, K. Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. Mol. Med. Rep., 2009, 2(6), 897-902.
[http://dx.doi.org/10.3892/mmr_00000189] [PMID: 21475918]
Gammone, M.A.; D'Orazio, N. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar. Drugs, 2015, 13(4), 2196-2214.
[http://dx.doi.org/10.3390/md13042196] [PMID: 25871295]
Maeda, H. Nutraceutical effects of fucoxanthin for obesity and diabetes therapy: a review. J. Oleo Sci., 2015, 64(2), 125-132.
[http://dx.doi.org/10.5650/jos.ess14226] [PMID: 25748372]
Woo, M.N.; Jeon, S.M.; Shin, Y.C.; Lee, M.K.; Kang, M.A.; Choi, M.S. Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol. Nutr. Food Res., 2009, 53(12), 1603-1611.
Fu, Y.Y.; Zhang, M.; Turner, N.; Zhang, L.N.; Dong, T.C.; Gu, M.; Leslie, S.J.; Li, J.Y.; Nan, F.J.; Li, J. A novel chemical uncoupler ameliorates obesity and related phenotypes in mice with diet-induced obesity by modulating energy expenditure and food intake. Diabetologia, 2013, 56(10), 2297-2307.
Zhang, Z.; Zhang, H.; Li, B.; Meng, X.; Wang, J.; Zhang, Y.; Yao, S.; Ma, Q.; Jin, L.; Yang, J.; Wang, W.; Ning, G. Berberine activates thermogenesis in white and brown adipose tissue. Nat. Commun., 2014, 5(5), 5493.
[http://dx.doi.org/10.1038/ncomms6493] [PMID: 25423280]
Ma, X.; Xu, L.; Alberobello, A.T.; Gavrilova, O.; Bagattin, A.; Skarulis, M.; Liu, J.; Finkel, T.; Mueller, E. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab., 2015, 22(4), 695-708.
Wankhade, U.D.; Shen, M.; Yadav, H.; Thakali, K.M. Novel browning agents, mechanisms, and therapeutic potentials of brown adipose tissue. BioMed Res. Int., 2016, 2016, 2365609
[http://dx.doi.org/10.1155/2016/2365609] [PMID: 28105413]
Silvester, A.J.; Aseer, K.R.; Yun, J.W. Dietary polyphenols and their roles in fat browning. J. Nutr. Biochem., 2019, 64, 1-12.
[http://dx.doi.org/10.1016/j.jnutbio.2018.09.028] [PMID: 30414469]
Joo, J.I.; Kim, D.H.; Choi, J-W.; Yun, J.W. Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J. Proteome Res., 2010, 9(6), 2977-2987.
[http://dx.doi.org/10.1021/pr901175w] [PMID: 20359164]
Choi, J.H.; Kim, S.W.; Yu, R.; Yun, J.W. Monoterpene phenolic compound thymol promotes browning of 3T3-L1 adipocytes. Eur. J. Nutr., 2017, 56(7), 2329-2341.
Parray, H.A.; Lone, J.; Park, J.P.; Choi, J.W.; Yun, J.W. Magnolol promotes thermogenesis and attenuates oxidative stress in 3T3-L1 adipocytes. Nutrition, 2018, 50, 82-90.
[http://dx.doi.org/10.1016/j.nut.2018.01.017] [PMID: 29547798]
Gregoire, F.M.; Smas, C.M.; Sul, H.S. Understanding adipocyte differentiation. Physiol. Rev., 1998, 78(3), 783-809.
[http://dx.doi.org/10.1152/physrev.1998.78.3.783] [PMID: 9674695]
Gregoire, F.M. Adipocyte differentiation: from fibroblast to endocrine cell. Exp. Biol. Med. (Maywood), 2001, 226(11), 997-1002.
[http://dx.doi.org/10.1177/153537020122601106]
White, U.A.; Stephens, J.M. Transcriptional factors that promote formation of white adipose tissue. Mol. Cell. Endocrinol., 2010, 318(1-2), 10-14.
[http://dx.doi.org/10.1016/j.mce.2009.08.023] [PMID: 19733624]
Cristancho, A.G.; Lazar, M.A. Forming functional fat: a growing understanding of adipocyte differentiation. Nat. Rev. Mol. Cell Biol., 2011, 12(11), 722-734.
Hwang, J.T.; Lee, M.S.; Kim, H.J.; Sung, M.J.; Kim, H.Y.; Kim, M.S.; Kwon, D.Y. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother. Res., 2009, 23(2), 262-266.
[http://dx.doi.org/10.1002/ptr.2606] [PMID: 18844326]
Hwang, J-T.; Kim, S-H.; Lee, M-S.; Kim, S.H.; Yang, H-J.; Kim, M-J.; Kim, H-S.; Ha, J.; Kim, M.S.; Kwon, D.Y. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem. Biophys. Res. Commun., 2007, 364(4), 1002-1008.
Siraj, F.M.; SathishKumar, N.; Kim, Y.J.; Kim, S.Y.; Yang, D.C. Ginsenoside F2 possesses anti-obesity activity via binding with PPARγ and inhibiting adipocyte differentiation in the 3T3-L1 cell line. J. Enzyme Inhib. Med. Chem., 2015, 30(1), 9-14.
[http://dx.doi.org/10.3109/14756366.2013.871006] [PMID: 24666293]
Gu, W.; Kim, K.A.; Kim, D.H. Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol. Pharm. Bull., 2013, 36(1), 102-107.
[http://dx.doi.org/10.1248/bpb.b12-00558] [PMID: 23302642]
Park, D.; Yoon, M.; Compound, K. Compound K, a novel ginsenoside metabolite, inhibits adipocyte differentiation in 3T3-L1 cells: involvement of angiogenesis and MMPs. Biochem. Biophys. Res. Commun., 2012, 422(2), 263-267.
Liu, Q.; Zhang, X.L.; Tao, R.Y.; Niu, Y.J.; Chen, X.G.; Tian, J.Y.; Ye, F. Rhein, an inhibitor of adipocyte differentiation and adipogenesis. J. Asian Nat. Prod. Res., 2011, 13(8), 714-723.
Seo, J.B.; Choe, S.S.; Jeong, H.W.; Park, S.W.; Shin, H.J.; Choi, S.M.; Park, J.Y.; Choi, E.W.; Kim, J.B.; Seen, D.S.; Jeong, J.Y.; Lee, T.G. Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism. Exp. Mol. Med., 2011, 43(4), 205-215.
[http://dx.doi.org/10.3858/emm.2011.43.4.025] [PMID: 21389766]
Seo, J.B.; Park, S.W.; Choe, S.S.; Jeong, H.W.; Park, J.Y.; Choi, E.W.; Seen, D.S.; Jeong, J.Y.; Lee, T.G. Foenumoside B from Lysimachia foenum-graecum inhibits adipocyte differentiation and obesity induced by high-fat diet. Biochem. Biophys. Res. Commun., 2012, 417(2), 800-806.
Rahman, N.; Jeon, M.; Song, H.Y.; Kim, Y.S. Cryptotanshinone, a compound of Salvia miltiorrhiza inhibits pre-adipocytes differentiation by regulation of adipogenesis-related genes expression via STAT3 signaling. Phytomedicine, 2016, 23(1), 58-67.
[http://dx.doi.org/10.1016/j.phymed.2015.12.004] [PMID: 26902408]
Altaf, Q.A.; Barnett, A.H.; Tahrani, A.A. Novel therapeutics for type 2 diabetes: insulin resistance. Diabetes Obes. Metab., 2015, 17(4), 319-334.
de Luca, C.; Olefsky, J.M. Inflammation and insulin resistance. FEBS Lett., 2008, 582(1), 97-105.
[http://dx.doi.org/10.1016/j.febslet.2007.11.057] [PMID: 18053812]
Kajimoto, Y.; Kaneto, H. Role of oxidative stress in pancreatic beta-cell dysfunction. Ann. N. Y. Acad. Sci., 2004, 1011(1), 168-176.
[http://dx.doi.org/10.1196/annals.1293.017] [PMID: 15126294]
Matsuzawa-Nagata, N.; Takamura, T.; Ando, H.; Nakamura, S.; Kurita, S.; Misu, H.; Ota, T.; Yokoyama, M.; Honda, M.; Miyamoto, K.; Kaneko, S. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism, 2008, 57(8), 1071-1077.
[http://dx.doi.org/10.1016/j.metabol.2008.03.010] [PMID: 18640384]
Ravussin, E.; Smith, S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann. N. Y. Acad. Sci., 2002, 967(1), 363-378.
[http://dx.doi.org/10.1111/j.1749-6632.2002.tb04292.x] [PMID: 12079864]
Dandona, P.; Aljada, A.; Bandyopadhyay, A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol., 2004, 25(1), 4-7.
[http://dx.doi.org/10.1016/j.it.2003.10.013] [PMID: 14698276]
Ye, J. Mechanisms of insulin resistance in obesity. Front. Med., 2013, 7(1), 14-24.
Ding, L.; Li, J.; Song, B.; Xiao, X.; Zhang, B.; Qi, M.; Huang, W.; Yang, L.; Wang, Z. Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol. Appl. Pharmacol., 2016, 304, 99-109.
[http://dx.doi.org/10.1016/j.taap.2016.05.011] [PMID: 27208389]
Shao, W.; Yu, Z.; Chiang, Y.; Yang, Y.; Chai, T.; Foltz, W.; Lu, H.; Fantus, I.G.; Jin, T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One, 2012, 7(1), e28784
Zheng, Z.G.; Zhou, Y.P.; Zhang, X.; Thu, P.M.; Xie, Z.S.; Lu, C.; Pang, T.; Xue, B.; Xu, D.Q.; Chen, Y.; Chen, X.W.; Li, H.J.; Xu, X. Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation. Biochem. Pharmacol., 2016, 122, 42-61.
Fjære, E.; Aune, U.L.; Røen, K.; Keenan, A.H.; Ma, T.; Borkowski, K.; Kristensen, D.M.; Novotny, G.W.; Mandrup-Poulsen, T.; Hudson, B.D.; Milligan, G.; Xi, Y.; Newman, J.W.; Haj, F.G.; Liaset, B.; Kristiansen, K.; Madsen, L. Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. J. Biol. Chem., 2014, 289(23), 16032-16045.
[http://dx.doi.org/10.1074/jbc.M113.525220] [PMID: 24742673]
Ozcan, L.; Xu, X.; Deng, S.X.; Ghorpade, D.S.; Thomas, T.; Cremers, S.; Hubbard, B.; Serrano-Wu, M.H.; Gaestel, M.; Landry, D.W.; Tabas, I. Treatment of obese insulin-resistant mice with an allosteric MAPKAPK2/3 inhibitor lowers blood glucose and improves insulin sensitivity. Diabetes, 2015, 64(10), 3396-3405.
Xu, N.; Zhang, L.; Dong, J.; Zhang, X.; Chen, Y.G.; Bao, B.; Liu, J. Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in mice. Mol. Nutr. Food Res., 2014, 58(6), 1258-1268.
Zhang, L.; Han, Y.J.; Zhang, X.; Wang, X.; Bao, B.; Qu, W.; Liu, J. Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages. Diabetologia, 2016, 59(10), 2219-2228.
Luft, V.C.; Schmidt, M.I.; Pankow, J.S.; Couper, D.; Ballantyne, C.M.; Young, J.H.; Duncan, B.B. Chronic inflammation role in the obesity-diabetes association: a case-cohort study. Diabetol. Metab. Syndr., 2013, 5(1), 31.
[http://dx.doi.org/10.1186/1758-5996-5-31] [PMID: 23806173]
Monteiro, R.; Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome Chronic in-flammation in obesity and the metabolic syndrome. Mediators Inflamm., 2010, 2010, pii: 289645
[http://dx.doi.org/10.1155/2010/289645] [PMID: 20706689]
González-Chávez, A.; Elizondo-Argueta, S.; Gutiérrez-Reyes, G.; León-Pedroza, J.I. Pathophysiological implications between chronic inflammation and the development of diabetes and obesity. Cir. Cir., 2011, 79(2), 209-216.
Dixon, R.A.; Ferreira, D. Genistein. Phytochemistry, 2002, 60(3), 205-211.
Ibrahim, A.S.; El-Shishtawy, M.M.; Peña, A., Jr; Liou, G.I. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol. Vis., 2010, 16, 2033-2042.
Saisho, Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr. Metab. Immune Disord. Drug Targets, 2015, 15(3), 196-205.
[http://dx.doi.org/10.2174/1871530315666150316124019] [PMID: 25772174]
Evia-Viscarra, M.L.; Rodea-Montero, E.R.; Apolinar-Jiménez, E.; Muñoz-Noriega, N.; García-Morales, L.M.; Leaños-Pérez, C.; Figueroa-Barrón, M.; Sánchez-Fierros, D.; Reyes-García, J.G. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J. Pediatr. Endocrinol. Metab., 2012, 25(1-2), 41-49.
[http://dx.doi.org/10.1515/jpem-2011-0469] [PMID: 22570949]
Fidan, E.; Onder Ersoz, H.; Yilmaz, M.; Yilmaz, H.; Kocak, M.; Karahan, C.; Erem, C. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol., 2011, 48(4), 297-302.
Lu, A.; Wu, H. Structural mechanisms of inflammasome assembly. FEBS J., 2015, 282(3), 435-444.
[http://dx.doi.org/10.1111/febs.13133] [PMID: 25354325]
Honda, H.; Nagai, Y.; Matsunaga, T.; Okamoto, N.; Watanabe, Y.; Tsuneyama, K.; Hayashi, H.; Fujii, I.; Ikutani, M.; Hirai, Y.; Muraguchi, A.; Takatsu, K. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J. Leukoc. Biol., 2014, 96(6), 1087-1100.
[http://dx.doi.org/10.1189/jlb.3A0114-005RR] [PMID: 25210146]
Oh, D.Y.; Walenta, E.; Akiyama, T.E.; Lagakos, W.S.; Lackey, D.; Pessentheiner, A.R.; Sasik, R.; Hah, N.; Chi, T.J.; Cox, J.M.; Powels, M.A.; Di Salvo, J.; Sinz, C.; Watkins, S.M.; Armando, A.M.; Chung, H.; Evans, R.M.; Quehenberger, O.; McNelis, J.; Bogner-Strauss, J.G.; Olefsky, J.M.A.A. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med., 2014, 20(8), 942-947.
[http://dx.doi.org/10.1038/nm.3614] [PMID: 24997608]
Lederberg, J. Infectious history. Science, 2000, 288(5464), 287-293.
[http://dx.doi.org/10.1126/science.288.5464.287] [PMID: 10777411]
Lin, C.S.; Chang, C.J.; Lu, C.C.; Martel, J.; Ojcius, D.M.; Ko, Y.F.; Young, J.D.; Lai, H.C. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed. J., 2014, 37(5), 259-268.
[http://dx.doi.org/10.4103/2319-4170.138314] [PMID: 25179725]
DiBaise, J.K.; Zhang, H.; Crowell, M.D.; Krajmalnik-Brown, R.; Decker, G.A.; Rittmann, B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc., 2008, 83(4), 460-469.
[http://dx.doi.org/10.4065/83.4.460] [PMID: 18380992]
Shen, J.; Obin, M.S.; Zhao, L. The gut microbiota, obesity and insulin resistance. Mol. Aspects Med., 2013, 34(1), 39-58.
[http://dx.doi.org/10.1016/j.mam.2012.11.001] [PMID: 23159341]
Murphy, E.F.; Cotter, P.D.; Healy, S.; Marques, T.M.; O'Sullivan, O.; Fouhy, F.; Clarke, S.F.; O'Toole, P.W.; Quigley, E.M.; Stanton, C.; Ross, P.R.; O'Doherty, R.M.; Shanahan, F. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut, 2010, 59(12), 1635-1642.
[http://dx.doi.org/10.1136/gut.2010.215665] [PMID: 20926643]
de La Serre, C.B.; Ellis, C.L.; Lee, J.; Hartman, A.L.; Rutledge, J.C.; Raybould, H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299(2), G440-G448.
[http://dx.doi.org/10.1152/ajpgi.00098.2010] [PMID: 20508158]
Verdam, F.J.; Fuentes, S.; de Jonge, C.; Zoetendal, E.G.; Erbil, R.; Greve, J.W.; Buurman, W.A.; de Vos, W.M.; Rensen, S.S. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring), 2013, 21(12), E607-E615.
Kootte, R.S.; Vrieze, A.; Holleman, F.; Dallinga-Thie, G.M.; Zoetendal, E.G.; de Vos, W.M.; Groen, A.K.; Hoekstra, J.B.L.; Stroes, E.S.; Nieuwdorp, M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab., 2012, 14(2), 112-120.
Hu, Y.; Davies, G.E. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 2010, 81(5), 358-366.
[http://dx.doi.org/10.1016/j.fitote.2009.10.010] [PMID: 19861153]
Zhang, X.; Zhao, Y.; Zhang, M.; Pang, X.; Xu, J.; Kang, C.; Li, M.; Zhang, C.; Zhang, Z.; Zhang, Y.; Li, X.; Ning, G.; Zhao, L. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One, 2012, 7(8), e42529
Xie, W.; Gu, D.; Li, J.; Cui, K.; Zhang, Y. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One, 2011, 6(9), e24520
Masumoto, S.; Terao, A.; Yamamoto, Y.; Mukai, T.; Miura, T.; Shoji, T. Non-absorbable apple procyanidins prevent obesity associated with gut microbial and metabolomic changes. Sci. Rep., 2016, 6, 31208.
[http://dx.doi.org/10.1038/srep31208] [PMID: 27506289]
Witkamp, R.F. Biologically active compounds in food products and their effects on obesity and diabetes. Comp. Nat. Prod., 2010, 3, 509-545.
Title:Recent Development on Anti-Obesity Compounds and their Mechanisms of Action: A Review
VOLUME: 27	ISSUE: 21
Author(s):Yixing Qiu, Huanghe Yu , Rong Zeng, Shiyin Guo, Muhammad Daniyal, Zeyu Deng, Aibing Wang* and Wei Wang*
Affiliation:TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, Hunan, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, The Key Laboratory of Animal Vaccine & Protein Engineering, College of Veterinary Medicine, Hunan Agricultural University, Changsha 410128, Hunan, TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Drug Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208
Keywords:Obesity, active compounds, mechanisms of action, lipid metabolism and energy expenditure, adipocyte differentiation, insulin resistance, chronic inflammation, gut microorganism.
Abstract:Obesity, associated with a series of complications such as diabetes, hypertension, and heart disease, is a great threat to human health and leads to increased morbidity and mortality. Despite the presence of anti-obesity agents on the market, the application of these drugs is limited because of their typical side effects. More effective and safe weight-loss drugs are being pursued by many researchers, correspondingly, growing small molecules and natural products with anti-obesity effects have been identified and the molecular mechanisms underlying the action of the novel and known compounds have at least partially been revealed. Therefore, the field does witness great progress year by year. In this review, we intend to provide a comprehensive and updated view on the known and novel compounds which possess anti-obesity effects and further classify them according to the molecular mechanisms of their actions in regulating the major anti-obesity pathways.
Yixing Qiu, Huanghe Yu , Rong Zeng, Shiyin Guo, Muhammad Daniyal, Zeyu Deng, Aibing Wang* and Wei Wang*, "Recent Development on Anti-Obesity Compounds and their Mechanisms of Action: A Review", Current Medicinal Chemistry (2020) 27: 3577. https://doi.org/10.2174/0929867326666190215114359
https://doi.org/10.2174/0929867326666190215114359 Print ISSN
Published on: 16 June, 2020
Page: [3577 - 3597]
DOI: 10.2174/0929867326666190215114359
HTML: 3
Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients
Current Rheumatology Reviews
Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Cardiovascular Risk Factors and Dietary Patterns
Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry
Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study
Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping and Synthesis
Letters in Drug Design & Discovery
Atrial Tachycardias Occurring Late After Open Heart Surgery
Intramolecular Processes and Their Applications in Prodrugs Approaches- Experimental and Computational Studies
Current Organic Chemistry
Immune Checkpoint Inhibitors: Basics and Challenges
Food Proteins as Source of Opioid Peptides-A Review
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus
Peptide Deformylase: A New Target in Antibacterial, Antimalarial and Anticancer Drug Discovery
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Fragment Based Drug Design: From Experimental to Computational Approaches
Recent Researches in Triazole Compounds as Medicinal Drugs
Therapeutic Proteins for Treatment of Corneal Epithelial Defects
Neglected Diseases Caused By Bacterial Infections
Medical Applications of Collagen and Collagen-Based Materials


text:
Gordon Funeral Homes
Sara Jane Holben
November 13, 1937 ~ January 1, 2022 (age 84)
Age 84, of Canton, passed away Sat., Jan. 1, 2022, at the Canton Christian Home. She was born Nov. 13, 1937 in Fairhope, OH, a daughter of the late Virgil and Beulah (Lautzenheiser) Adams, and was a North Canton resident except for ten years in California. Jane was a 1955 graduate of Louisville High School and retired from Mercy Medical Center after 28 years' service, in Patient Accounts. She was a member of SOLOS and was an avid reader.
In addition to her parents, she was preceded in death by her husband of 34 years, Richard Holben, in 1994, and a sister, Joanne Vaughn. Jane is survived by her daughter, Cindy Pincoe and Randy Frank, grandson, Alex Pincoe, step-grandchildren, Amanda (Ryan) Dietrich, and Sean (Fiancee' Deshia Pryor) Frank, sister, Norma Elsaesser, and two sisters-in-law, Barb Beck and Drenna Baum.
Friends may call Wed. 4-6 p.m. at the Formet-Clevenger & Gordon Funeral Home. There will be no formal service. The family would like to thank the staff of the Canton Christian Home for all the love and kindness they gave to Jane during her stay there. In lieu of flowers, contributions in Jane Holben's memory may be made to the Canton Christian Home Benevolent Fund, 2550 Cleveland Ave. NW, Canton, OH 44709. Condolences may be sent to: www.gordonfuneralhomes.com
Gordon (330) 456-4766
To send flowers to the family or plant a tree in memory of Sara, please visit our floral store.
Formet-Clevenger & Gordon Funeral Home
1803 Cleveland Ave. NW
© 2022 Gordon Funeral Homes. All Rights Reserved. Funeral Home website by CFS & TA | Terms of Use | Privacy Policy

redpajama_set_name: RedPajamaCommonCrawl


Magnesium is a very important mineral needed for a normal, healthy metabolism. It is an essential mineral that is necessary for numerous functions within the body. It helps reduce immune reactions and malabsorption related to celiac disease. Magnesium is a component of mineralized bone, it works together with calcium and vitamin D to help keep bones and teeth strong, and also promotes proper muscular development. It supports normal functioning of muscle and nervous tissue, and is required for release of energy. It also helps the body handle stress. Individuals suffering from headaches and/or insomnia have reported reduction of symptoms with magnesium use. Last, but not least, magnesium promotes cardiovascular health by facilitating normal platelet activity and helping to regulate cholesterol levels.
Magnesium is found in the following foods: dark leafy green vegetables, bananas, avocados, nuts, soy products, whole grains, and beans. Adult females should consume between 310-320 mg daily and adult males should consume between 400-420 mg daily.


The last episode in a seven-part series, British Documentary Movement, Vol. 7: Festival of Britain examines the history of non-fiction filmmaking directly after World War II. Humphrey Jennings made his last documentary when he was commissioned to direct Family Portrait for the Festival of Britain. The resulting film was a poetic and optimistic look at England as a nation. Meanwhile, Paul Dickson detailed the life of a mining town in David. His efforts are joined by John Eldridge who contributed an artistic and stylized documentary about Edinburgh in Waverly Steps.


text:
From Banker to Screenwriter, the Man behind "Tapestry"
The latest Christian film starring Stephen Baldwin is a window onto how God allows pain and setbacks to draw us closer.
Tina Louise, Stephen Baldwin & Burt Young in a promotional poster for "Tapestry."
Turning an idea into a movie is quite a mean feat, even for seasoned industry insiders. As a veteran of the faith-based genre - Kevin Downes - said in a recent social media post, it "always seems like a Herculean effort."
So imagine what the journey must have been like for Rob DePalo when he first put pen to paper, as it were, for a short story based on his own experiences. In the finance industry his whole life, he had enjoyed writing as a boy and even considered getting into journalism after college. Things didn't work out that way, though.
Screenwriter and producer Rob DePalo. Image from his Facebook page.
It may sound clichéd, but God works in mysterious ways. About a decade ago, He began to lay the groundwork in DePalo's life for what would become Tapestry, a film that stars Stephen Baldwin, Tina Louise - who was Ginger on Gilligan's Island - and Burt Young, best known for his role as Paulie in the Rocky franchise. That groundwork came in the form of setbacks - both professional and personal - that would also bring DePalo into a closer walk with the Lord.
He was demoted at work and transferred from Brooklyn to an office in Manhattan. His mother then fell ill and he was undergoing difficulties in his marriage and with his children. In an interview with Christian Cinema, DePalo says a seemingly chance meeting with an old acquaintance he hadn't seen in 30 years served as the catalyst for change.
"He asked me why I didn't become a writer because I had always been good at it as a young guy...Then more people I met talked about how I should be writing and got me thinking about the role God was playing. I came to see those interactions as God-orchestrated events."
DePalo eventually showed his short story to a co-worker at the new job site, Mike Yacovone - he would go on to serve as producer and actor in Tapestry - who had connections in the film industry. He encouraged DePalo to turn the story into a screenplay. Once that was done, the plan was for DePalo to fund an ultra low-budget production of about $30,000 with unknown actors.
But someone had a connection to Stephen Baldwin, a committed Believer and fixture in the Christian movie genre. When he saw the script, he said he wanted to play the lead character, Ryan, who endures many of the same hardships DePalo had and is ultimately led closer to God. That changed everything. The budget went up to about $200,000 and more seasoned actors were brought in to round out the cast.
It took five years of what DePalo called "clawing and scratching" to finish the project, on which he was also a producer. But the journey, despite all the difficulties, really strengthened his faith.
"Since writing the story and making the movie, I really sense that God is present in my life. I never saw God as an active participant in day-to-day life. Now I see God is with us."
DePalo has apirations to make more movies, though he is still currently working in the banking sector in the New York area. If you'd like to see his inaugural effort, Tapestry, you can do so via ChristianCinema.com or Amazon.com. In the meantime, the trailer below will give you a better sense for the film.
Christian Director Harold Cronk Writes a Children's Book for Boys
Dallas Jenkins Discusses the Most Controversial Moment from "The Chosen"


text:
Q: How to open a new window and close the current when clicked on button in electron application? I want to open a new window when the person clicks on the button in the first window displayed when the electron application is started.
Let's suppose I want to display a new html file called 'second.html' whenever a person clicks on the button displayed on the application where mainWindow.html is currently loaded.
index.js file
const url = require('url');
const path = require('path');

const { app, BrowserWindow, Menu } = electron;

let mainWindow;
let { ipcMain } = electron;
let runAnalysisWindow

//Listen for an app to be ready.
app.on('ready', function() {
    //Create a new Window.
    mainWindow = new BrowserWindow({});
    //Load html into Window.
    mainWindow.loadURL(url.format({
        pathname: path.join(__dirname, 'mainWindow.html'),
        protocol: 'file:',
        slashes: true
    }));
    //Build menu from template.
    const mainMenu = Menu.buildFromTemplate(mainMenuTemplate);
    //Insert the menu.
    Menu.setApplicationMenu(mainMenu);

});

app.on('closed', function() {
    mainWindow = null;
});

// Quit when all windows are closed.
app.on('window-all-closed', function() {
    // On OS X it is common for applications and their menu bar
    // to stay active until the user quits explicitly with Cmd + Q
    if (process.platform !== 'darwin') {
        app.quit()
    }
})

app.on('activate', function() {
    // On OS X it's common to re-create a window in the app when the
    // dock icon is clicked and there are no other windows open.
    if (mainWindow === null) {
        createWindow()
    }
})

//Create menu template.

const mainMenuTemplate = [{
    label: 'File',
    submenu: [{
            label: 'Run Analysis'
        },
        {
            label: 'Stop Analysis'
        },
        {
            label: 'Generate Report'

        },
        {
            label: 'Previous Reports'
        },
        {
            label: 'Help'
        },
        {
            label: 'Quit',
            accelerator: process.platform == 'darwin' ? 'Command+Q' : 'Ctrl+Q', //Use the shortcut to quit the app in windows and mac.
            click() {
                app.quit();
            }
        }
    ]

}];

HTML File (mainWindow.html):
<!DOCTYPE html>
<html lang="en">
<head>
    <title>SparrowAI</title>
    <style>
    .button {
    background-color: #4CAF50; /* Green */
    border: none;
    color: white;
    padding: 16px 32px;
    text-align: center;
    text-decoration: none;
    display: inline-block;
    font-size: 16px;
    margin: 4px 2px;
    -webkit-transition-duration: 0.4s; /* Safari */
    transition-duration: 0.4s;
    cursor: pointer;
    }

    .button1 {
    background-color: Transparent;
    color: white;
    border: 2px solid #ffffff;
    }
    .button1:hover {
    background-color: #555555;
    color: white;
    }
    </style>
</head>
<body background = "log_page.jpg">

<button type="button" class="button button1"> Login</button>

</body>
</html>

A: You could send the ipc message to open new html, using ipcRenderer,
ipcRenderer.send('button-click');

catch the click in main process like this
ipcMain.on('button-click',()=>{
    //Load html into Window.
    mainWindow.loadURL(url.format({
        pathname: path.join(__dirname, 'second.html'),
        protocol: 'file:',
        slashes: true
    }));
})

redpajama_set_name: RedPajamaStackExchange


Armstrong has announced the filling of engineering jobs in Tampa.
Armstrong Forensic Engineers today announced that it has expanded its operations in Florida with the hiring of Senior Consultant Rachel Keller and additional support staff. These hires will serve to handle Armstrong's growing client base in Tampa and throughout Florida.
Ms. Keller is a Professional Engineer with Mechanical Engineering degrees from Virginia Tech and Florida State University. She has extensive experience in accident reconstruction involving tractor-trailers, motorcycles, and automobiles. She is also experienced in the area of injury causation and seat belt analysis, having directed projects that required the engineering analysis of accident and material evidence to determine injury mechanisms or if injuries were consistent with accident evidence.
Armstrong Forensic Engineers is a national forensic services firm providing technical consulting to legal, insurance, and corporate clients. The company's professional engineers and consultants are skilled in many disciplines, offering reconstruction, scientific analysis, and expert testimony of traffic accidents and all types of mechanical, civil, or electrical engineering failures.
Visit the company on the web at www.armstrongforensic.com or call (866) 948-8010.
A Tampa-based company has successfully recruited for consultant jobs in Tampa.
Many companies are soliciting applications for Tampa Bay sales jobs.
Auto insurer Progressive announced it will be hiring more than 240 people at its Tampa Bay call center over the next four months to handle a surge in customers across the country.
Many companies are announcing a plethora of new customer service jobs in Tampa that are available.
You are currently browsing the Finding Jobs in Tampa weblog archives for October, 2010.


text:
Team Nigeria climbs to 8th position
by Onyewuchi Nwachukwu, Gold Coast, Australia
in News Update, Sports
• Adekuoroye celebrates victory over Pooja Dhanda of India in the Womens Freestyle 57kg gold medal match Gold Coast, Australia yesterday
Nigeria last night swept to an unprecedented four gold medals and took a giant move to number 8 on the medals table ahead of such big countries like Jamaica, Malaysia, Kenya, and Botswana. South Africa remains the only African country ahead of Nigeria on the table as they maintained their 5th position with 13 Gold, 10 Silver and 12 bronze medals. Nigeria has 8 Gold, 5 Silver and 5 Bronze medals.
Blessing Oborodudu started a night to remember for Nigeria with a stunning victory in the 68 kg freestyle against Daniella Lappage of Canada winning 3–1 to add to the haul of Nigeria's precious gold. When Odunayo Adekuroye stepped to the mat, the hall exploded with sporadic applause against her India's opponent, Pooja Dhunda.
As they tried themselves for size, tension soared as Odunayo was warned and a point deducted from her. She did not look perturbed. When she finally got a real hold on her, she pinned her to the mat, turned and twisted like a Crocodile overwhelming its prey. The Nigerian garnered five points. As they continued with victory moving towards Nigeria, the Indian in a flash produced a stunning move that saw her amassing five points.
Odunayo, however, took victory beyond her and ended the glorious night on a victorious note beating her 7–5 to take the gold.
An overwhelmed coach swept her off her feet and hauled her on his head to celebrate the gold. Odunayo had other ideas. Decked with a Nigerian flag, she danced to what has become a signature dance and the crowd roared in appreciation.
Oluwatobilola Amusan also won gold in the 100m Women hurdle to keep Nigeria's flag flying. The gold rush was not over as Suwaibidu Galadima, a Para athlete, capped the night with yet another gold medal in the T47 100 m final.
Galadima led the field from beginning to finish 11:04secs. The 4 x 100 m Relay men got a bronze medal with a time 38:52secs. Amos Daniel also won a bronze in the Men's 65 kg Freestyle.
Tags: Team Nigeria
Table Tennis Nigeria out of Men's Doubles
Protesters storm Govt House with coffin of slain pastor
Alleged N64bn fraud: ICPC to resume prosecution of Ehindero


Added Competitive Intelligence subscription package.
Added Spotfire extension licenses to portal.
Added API endpoint to upload Spotfire library items.
Added API feature package. Org admins can now generate portal API keys if they have the package enabled.
Added select, single item relation, and multiple item relation term property types.
Updated organization KPIs to display previous year's Q4 KPIs.
Updated Change Log location to point to a support article rather than a static page.
Updated organization registration page UI.
Updated Boolean term property type value selection.
Improved the edit term properties modal when there are more than 8 term properties.
Updated training names to reflect 2018 course catalog names.
Updated default background image for users.
Added industry to organizations that is set when an org request is accepted.
Added user's job title to their profile when an org request is accepted.


Housse De Couette En Satin De Coton Housse De Couette Linge De Lit Haut De Gamme Garnier Thiebaut Housse De Couette Indigo Bleu Housse De Couette En Satin De Coton 4 HOUSSE DE COUETTE INDIGO BLEU is one of pictures thet are related with the picture before in the collection gallery. If you would like to see the Housse De Couette En Satin De Coton Housse De Couette Linge De Lit Haut De Gamme Garnier Thiebaut Housse De Couette Indigo Bleu Housse De Couette En Satin De Coton 4 HOUSSE DE COUETTE INDIGO BLEU in High Resolution [HD Resolution] version, please press the right click on picures/image then choose "Save as Image" option, and done. You will get Housse De Couette En Satin De Coton Housse De Couette Linge De Lit Haut De Gamme Garnier Thiebaut Housse De Couette Indigo Bleu Housse De Couette En Satin De Coton 4 HOUSSE DE COUETTE INDIGO BLEU pictures that you want. The exactly dimension of Housse De Couette En Satin De Coton Housse De Couette Linge De Lit Haut De Gamme Garnier Thiebaut Housse De Couette Indigo Bleu Housse De Couette En Satin De Coton 4 HOUSSE DE COUETTE INDIGO BLEU was 1000x1000 pixels. You can also look for some pictures by collection on below this picture. Find the other picture or article about Housse De Couette En Satin De Coton Idees De Dcoration here. We hope it can help you to get information of the picture.


text:
Game Day: Louisville at Memphis
By Mike Rutherford@CardChronicle Oct 10, 2008, 7:00am EDT
Share All sharing options for: Game Day: Louisville at Memphis
LOUISVILLE CARDINALS (2-2, 0-1) At MEMPHIS TIGERS (3-3, 1-2)
Game Time: 8 p.m.
Location: Liberty Bowl: Memphis, Tenn.
Television: ESPN
Announcers: Sean McDonough/Chris Spielman/Rob Stone
Favorite: Louisville by 6.5
All-Time Series: Louisville leads 21-19
Last Meeting: Louisville won 56-49 in 2004
Excitement Level: 5.9
We probably should have brought back the anxiety meter for this one, as I'm definitely more anxious about losing this one than I am excited about winning it.
Game Attire: Black Zack Stoudt jersey
I'm laying full blame for the UConn loss on the second-string hat. If the Tigers pull the upset then the jersey will almost assuredly be spending the rest of the winter in the closet. Do somethin', Stoudt.
Rock Keys Playing Alert Level: Magic Mint (It's not going to happen and you need to find a new player)
Predicted Star of the Game: Brock Bolen
How about triple digits and multiple visits to the endzone?
Notable and Quotable
--Memphis leads the all-time series in the Bluff City 11-10, but haven't defeated the Cards at home since 1997.
--Louisville is 9-3 all-time on Oct. 10.
--In the last six meetings between these two teams, the winner has scored more than 30 points.
--Memphis is 4-5 all-time on Oct. 10, and 49-54-11 on games played on Fridays.
--Steve Kragthorpe holds a 2-0 record as a head coach against Memphis.
--Through four games, Louisville has been outscored 48-12 in the fourth quarter.
--Memphis defensive tackle Clinton McDonald is currently tied for the national lead with seven sacks.
--"It's been a great rivalry for Louisville. We've talked a little bit about it with our team, and we'll talk to them more about it as the game gets closer. These schools have played for a long, long time, particularly when these two schools were independents." --Steve Kragthorpe
--"Whenever you get Louisville and Memphis together, it's always good stuff." --Tommy West
--"Arkelon Hall is really playing good football for them right now. He's making some plays with his feet and throwing the ball down the field with great accuracy. They've got a great group of wide receivers and they're running the ball well on offense." --Steve Kragthorpe
--"The season is obviously not over. Nobody is down in the dumps, but we're a little on edge to get back on the field again." --Eric Wood
--"I do not care for the Memphis State, nor am I particularly fond of their Tiger mascot." --Mike Rutherford
"There's some bad blood similar to Kentucky and Louisville. We know this is a big game for them, and it's a big game for us."--Eric Wood


Candidate must possess at least Diploma in Business Studies/Administration/Management, Economics, Finance/Accountancy/Banking or equivalent.
Required Skill(s): Analytical/critical thinking, Adaptability, Research skills, problem identification and solution skill, comunication skill, forecasting, Accounting.
EF Education First is a global education company focusing on language, academic, cultural exchange, and travel programs. With a mission to open the world through education, EF was founded in 1965. In the following section, you will find descriptions of EF's different businesses.
EF Education First is organized in three divisions: EF Language and Schools, EF Cultural Exchange, and EF Educational Travel. Each division has several different businesses.
Entri ini ditulis di Lowongan Keuangan, Lowongan Pendidikan dan ber-tag karir, loker, lowongan, lowongan kerja pada 15 April 2018 oleh admin.


text:
ATPases signal
ATPases are a class of enzymes
Drug relapse is a recurring problem among addicts, even following
Drug relapse is a recurring problem among addicts, even following long periods of drug abstinence. This behavior can be modeled in animals using either extinction training or withdrawal paired with drug prime-, cue and/or stress-induced reinstatement tests. Recently, Mahler et al. [17•] used DREADDs to examine the contribution of subregions of the ventral pallidum (VP) in cue and cocaine prime-induced reinstatement following withdrawal.
They found that increasing Gi/o signaling in rostral VP neurons decreased cue-induced but not cocaine prime-induced reinstatement whereas the same manipulation in caudal VP had the opposite effect; that is it attenuated cocaine prime-induced but not cue-induced reinstatement http://www.selleckchem.com/products/azd5363.html [17•]. Additionally, both activation of inhibitory hM4Di DREADDs in rostral VP terminals in the VTA and functional disconnection of the rostral VP from dopamine neurons in the VTA (via unilateral expression and activation of
hM4Di in rostral VP combined with contralateral expression and activation of hM4Di only in tyrosine Dactolisib price hydroxylase (TH+) of the VTA) attenuated cue prime-induced reinstatement, demonstrating that rostral VP connectivity to dopamine neurons in the VTA is crucial for driving this form of reinstatement [17•]. Another recent study using DREADDs to investigate the cell types that modulate ethanol-seeking following self-administration [18••]. They found that increasing Gq signaling selectively in astrocytes in the nucleus accumbens core following a 3-week period of abstinence decreased motivation for ethanol, as assessed by decreases in breakpoints in a progressive ratio schedule of reinforcement. This manipulation
also facilitated responding for intracranial self-stimulation but had no effect on motor activity [18••]. The studies MycoClean Mycoplasma Removal Kit described in this review demonstrate how new technologies, such as DREADD receptors, are being implemented in order to understand the circuitry and intracellular signaling processes underlying the different phases of addiction. These techniques are allowing us to answer circuit-mapping questions that have previously been unaddressable due to technical limitations. For example, it has been difficult to isolate the contribution of subsets of MSNs or astrocytes in addiction-related behaviors because the neurons are physically intermingled and pharmacological approaches are limited due to multiple cell types expressing the same receptor (e.g. Gi/o-coupled dopamine D2 receptors are expressed in indirect MSNs as well as cholinergic interneurons in the striatum). As described above, we can circumvent these issues by expressing DREADDs under the control of selective promoters in order to achieve cell-type specific manipulations.
For detection and/or quantification of cell death, forward/sidewa
For detection and/or quantification of cell death, forward/sideward light scattering analysis and AnnexinV/propidium iodide-staining were used as described (Bernhard et al., 2003). AnnexinV/PI− staining allows the discrimination of intact viable cells (AnnexinV− negative and PI− negative), early apoptotic (AnnexinV− positive and
PI− negative) and necrotic cells (AnnexinV− positive and PI− positive). The number of viable cells was determined using the XTT assay (Biomol GmbH, Hamburg, Germany). HUVECs were seeded into gelatine coated 96-well plates. After 24 h the medium was replaced by fresh medium and the cells were treated with various Cd concentrations www.selleckchem.com/products/DAPT-GSI-IX.html for the indicated times. For further details see manufacturers' instructions. The amount of MK-2206 manufacturer lactate dehydrogenase (LDH) released from cells was quantified using the LDH cytotoxicity kit II (Biovision) according to the manufacturer's instructions. For the detection and quantification of nuclear DNA content, HUVECs were seeded into gelatine coated 6-well plates and allowed to adhere over night. After replacing the medium with fresh medium, the cells were incubated with various Cd concentrations for the indicated times. After enzymatic detachment, the cells were permeabilized with saponin (1 mg/ml), stained with propidium iodide (50 μg/ml) and analysed and quantified
by flowcytometry using a Cytomics FC 500 (Beckmann Coulter, Brea, CA, USA). To analyse the subcellular localization of DNAse II, HUVECs were treated with Cd for the indicated times. After treatment, the cells were washed with PBS and fixed with 4% PFA for
3 min at room temperature. Fixed cells were washed with PBS and permeabilized with 0.3% Triton X-100 for 30 min. Following an additional washing step with PBS, non-specific binding sites were blocked with 1% bovine serum albumin (BSA) in PBS for 30 min at room temperature followed by staining with primary antibody against DNAse II (mouse polyclonal antibody, Abnova GmbH, Heidelberg, Germany; 10 μg/ml) for 1 h at room temperature. After 3 washing steps with PBS, the cells were incubated with secondary antibody (Alexa Fluor 488, mafosfamide goat anti-mouse, Invitrogen, Carlsbad, CA, USA) for 1 h in the dark and at room temperature. Thereafter, the monolayer was washed 3 times with PBS and nuclear staining was performed using propidium iodide (1 μg/ml) for 8 min at room temperature in the dark. After 3 final washing steps, cells were mounted in ProLong Gold (Invitrogen, Carlsbad, CA, USA) and analysed using a LSM 510 Meta attached to an Axioplan 2 imaging MOT using ZEN software (Zeiss, Oberkochen, Germany). To analyse cytosolic nuclease activity of Cd treated HUVECs, nuclear DNA was extracted from endothelial cells using a DNA purification kit (Promega GmbH, USA). Nuclear DNA (2 μg) was then incubated with cytosolic extracts of Cd-treated HUVECs and controls (30 μg) for 3 h at 37 °C. DNA fragmentation was analysed by agarose gel electrophoresis (0.5%).
One important milestone linking AGEs, oxidative stress and inflam
One important milestone linking AGEs, oxidative stress and inflammatory pathways was the discovery of RAGE (receptor for advanced glycation end-products) that is a multi-ligand receptor of the immunoglobulin superfamily long implicated in inflammation, diabetes and its complications, nephropathy, neurodegeneration and cancer [17•]. As depicted in Figure 1 cellular signaling due to AGE–RAGE interactions seems to be a key component in pro-oxidative pro-inflammatory condition in these pathologies, and suppressing RAGE
expression or enhancing other mechanisms to block RAGE–AGE interaction has been postulated as mechanisms to mitigate the carbonyl stress. Soluble forms of RAGE Selleck UK-371804 in the circulation (s-RAGE) seem to exert anti-atherogenic effects as a decoy receptor that abolishes RAGE signaling. The C-terminal truncated form of RAGE mRNA lacks the sequences encoding the transmembrane and intra-cytoplasmic domains. The extracellular domain of RAGE thereby produced, is released from cells, found in the circulation in humans. It Selleckchem KU-60019 has been named endogenous secretory RAGE (esRAGE) and may play a role in cardiovascular disease. EsRAGE may then exert a decoy function: a feedback mechanism has been proposed by which
esRAGE prevents RAGE signaling. It has also been suggested that some sRAGE isoforms that could act as decoy receptors may be cleaved proteolytically from the native RAGE expressed on the cell surface, suggesting heterogeneity of the origin and nature of sRAGE [18]. In summary, AGE formation may thus accelerate pathological process through two general mechanisms which can be either non-receptor-dependent and receptor mediated [19] (Figure 2). The growing interest
in the relationship of chronic diseases and AGEs resulted in an increased number of papers and comprehensive reviews in the international literature. Histamine H2 receptor Research has encompassed all relevant aspects, such as AGEs in hypertension, cardiovascular risk, insulin resistance, oxidative stress [9••], [17•] and [20•] the main discoveries that link the Maillard reaction with health and nutrition [1], [10•] and [11] the role of RAGEs and mechanisms associated in chronic diseases [8], [17•], [21], [22] and [23]. At the center of this discussion lies the question whether dietary AGEs or Maillard reaction products (MRP) actually play a role in increasing the risk of non-communicable diseases and/or their complications [24]. The discovery and elucidation of the glycation reaction and its consequences in living organisms lead to the 'carbonyl stress theory' [16], [25] and [26]. This theory proposes that increasing ingestion of Maillard reaction products from processed foods, in the last decades, increases the pool of circulating carbonyl compounds and, therefore, the rate of AGEs generation with major consequences to health.
Benefits of laparoscopy include decreased postoperative pain and
Benefits of laparoscopy include decreased postoperative pain and quicker
return to function; moreover, laparoscopy may allow appropriate patients earlier access to definitive medical oncology treatments. The repeated cycle of inflammation, necrosis, and ulceration, alternating Epigenetic inhibitor with the deposition of granulation tissue during the healing phase, results in the development of raised areas of inflamed tissue that resemble polyps, called pseudopolyps, or may result in stricture formation. Such sequelae make endoscopic surveillance of dysplasia and cancer, and its management, a challenge. Colonic strictures are more common in Crohn's disease than in UC. Colonic strictures reportedly are found in 5% to 17% of patients with Crohn's colitis.10 Although data are lacking, colonic strictures have been reported in approximately 5% of UC patients. Rates of stricture
occurrence seem to be improving as medical treatments allow more patients to achieve remission. Z-VAD-FMK Colonic strictures in any setting should be considered malignant until proven otherwise. Gumaste and colleagues33 evaluated the Mount Sinai Hospital (New York) population of UC patients with strictures, and found 29% to be malignant. In Crohn's disease, despite a higher rate of stricture occurrence, the rate of malignant colorectal strictures was only 6.8%.34 There is no role for stricturoplasty in the primary management of colonic strictures in IBD. Strictures found at prior anastomotic sites in Crohn's disease may be judiciously dilated to allow for endoscopic evaluation of recurrence or technical problems from the original resection. Dysplasia and carcinoma at colonic strictures cannot always be detected preoperatively.35 The stricture must be able to be traversed, adequately examined, and biopsied. Even then, the risk of sampling error in a stricture
can be high; a biopsied portion may demonstrate inflammation and fail to show deeper malignancy. If malignancy cannot be excluded, oncologic resection is indicated. In UC, proctocolectomy is the only means to definitively diagnose or rule out carcinoma and to treat possible multifocal malignancy, and should be considered in the management of colonic UC stricture. Unlike UC, a segmental oncologic resection may be appropriate in Crohn's disease colorectal Sucrase stricture in a patient with limited segmental disease. Identification and treatment of dysplasia and colorectal cancer in IBD creates management challenges for the clinician. Treatment options for patients must be based on the understanding of differences in virulence between sporadic adenomas and inflammatory related dysplasia in patients with IBD. Surgical interventions should be based on patient morbidities, location and type of inflammation, and, most importantly, findings of dysplasia. Although the gold standard for oncologic resection is total proctocolectomy, many appropriate options exist that allow for intestinal continuity.
06 (95% CI − 0 8 to 0 6) compared
to heterozygotes (ß-coe
06 (95% CI − 0.8 to 0.6) compared
to heterozygotes (ß-coefficient 0.18; 95% CI 0.04 to 0.3). The threshold for having affected kidney function was based on 95th percentile of UB2M and concentrations of the individuals in the control area (corresponding to 1.49 mg/gCr UB2M and 20.3 U/gCr UNAG) for persons younger than 80 years. With this threshold 12.3% (N = 46) of the individuals in the medium and highly polluted areas had affected kidney function measured as UB2M and 15% (N = 56) measured as UNAG. Carriers of rs11076161 variant PFT�� genotypes (AA/AG) had an odds ratio of 2.8 (95% CI 1.4–5.8; P = 0.004) for UB2M above threshold compared to carriers of the GG genotype (adjusted for U-Cd; odds ratio = 3.3 (95% CI 1.5–7.2; P = 0.003, adjusted for U-Cd, sex, age, and smoking). None of the other SNPs affected
the risk of having affected kidney function measured as increased levels of UB2M or UNAG. Despite the known individual susceptibility of Cd toxicity, strikingly little is known about the role of our genetic background for Cd sensitivity. Here we have identified a genetic marker that modifies Cd-associated renal toxicity: with elevating Cd concentration the MT1A rs11076161 AA carriers demonstrated EPZ015666 ic50 the highest concentrations of UNAG and UB2M in urine. Also, we found a relationship between the MT1A rs11076161 AA genotype and B-Cd at high Cd exposures. One major strength is that the Cd exposure varies widely within this study: B-Cd ranged between 0.11 and 21, U-Cd between 0.05 and 75 μg/L. We analyzed UNAG and UB2M,
which are very sensitive biomarkers of renal tubular damage (Bernard, 2004). Furthermore, the study population was ethnically homogenous, and the study participants were recruited so that living Urocanase conditions, social and economic conditions and lifestyles were similar in the different areas. The genotyping was done with Taqman assays that are less prone to errors compared to restriction fragment length polymorphism analysis and quality control was strict. To our knowledge no other studies were performed of an appropriate study size suitable for genetic association studies with both well-defined exposure and kidney toxicity assessments. Initially, we kept the classification in exposure groups in the statistical analyses. However, as there was an overlap of B-Cd concentrations between the groups, the subjects were also grouped by B-Cd tertiles and in each tertile the associations between genotype and B-Cd, U-Cd, UNAG and UB2M were evaluated. This strengthened the associations for rs11076161. In this study multiple testing was performed: 3 polymorphisms and 4 outcomes were included in several multivariate regression models. Thus, there might problems with false positive findings. According to Wacholder et al. (2004) the false positive report probability is influenced by the significance level, statistical power and prior probability of the association tested.
e , focus on subject or object) during processing of sentences wi
e., focus on subject or object) during processing of sentences with varying word order from previous studies (e.g., Bornkessel et al., 2003 and Meng et al., 1999). Thus, absence of an N400 modulation in our study might be due to the fact that both characters of the scene were previously
mentioned in the lead-in context, and thus equally expected and accessible in the mental model. This is in line with Burkhardt and Roehm (2007), who argue that both entities within a coordinated noun phrase –in our experimental design the two animals in the lead-in (e.g., the owl and the hedgehog)– evoke the same representational status in terms of accessibility or saliency selleck screening library in the mental model. In the framework of the SDM, our design was effective in the modulation of costs for updating the current discourse model (late positivity, see above) but not for expectancy-based discourse linking processes (N400). Notably, in the topic condition, the topic of the context-question (e.g., What about the owl?) was directly repeated at the sentence initial position
of the target sentence (SO and OS sentences), whereas such a repetition was not present in the target sentence following the neutral context (e.g., What exactly is going on?). Accordingly, the context type in our study revealed a EPZ015666 molecular weight broadly distributed early positive peak time-locked to the onset of the target sentence independent of its word order. As the topic context induced a reduction of this early positivity relative to the neutral context, we suggest that this context effect might be confounded with basic processes of information encoding due to word repetition in one but not the other context. The early positivity we found showed about a similar peak and latency pattern as the positivity around
200 ms (c.f., P200) for which mixed results regarding its functional nature are reported in dependence on the experimental paradigm (e.g., Coulson et al., 2005, Federmeier and Kutas, 2001 and Friedrich and Kotz, 2007). As early modulations of ERPs, such as the P200, have commonly been associated with processes of basic information encoding (for visual stimuli see for instance Dunn et al., 1998, Evans and Federmeier, 2007 and Luck and Hillyard, 1994), we propose an interpretation of the reduced early positivity for repeated words in the topic condition in terms of a word repetition effect. Note that so far contradictory results have been reported with regard to amplitude and latency of ERPs elicited by word repetition: On the one hand side, some studies did not find a reduced but instead an enhanced early positivity for repeated words (see e.g., van Petten, Kutas, Kluender, Mitchiner, & McIsaac, 1991). However, in line with our data, a reduced early positivity for repeated words was found in word lists (e.g., Nagy and Rugg, 1989 and Rugg, 1985).
The dried gel pieces were rehydrated by adding 10 μL of ammonium
The dried gel pieces were rehydrated by adding 10 μL of ammonium bicarbonate buffer (50 mM) containing trypsin (20 ng/μL; Promega Trypsin Gold) and incubated for 16 h at 37 °C to ensure efficient peptide digestion. Gel pieces were washed with 30 μL of formic acid (5%, v/v) in acetonitrile (50% v/v) for 30 min. This step was repeated twice for complete peptide removal. Digestion solutions were pooled in low-retention micro tubes and the volume was reduced to approximately 10 μL by vacuum centrifugation. The samples Torin 1 manufacturer were desalted by reversed phase chromatography (Zip tips, C18 Ultra-Micro Prep Tip, Millipore Corporation, Bedford, MA). Briefly,
the Zip tips were initially washed three times with 10 μL 0.1% trifluoroacetic acid (TFA)/60% ACN and rinsed three times with 10 μL of 0.1% TFA. Then samples were loaded by aspiration before being eluted with 60% ACN/0.1% TFA. Tryptic digests, obtained as described previously, were submitted to reversed-phase nanochromatography coupled to nanoelectrospray high resolution mass spectrometry for identification. Four microliters of desalted tryptic peptide digest were initially applied to a 2 cm long (100 μm internal diameter) trap column packed with 5 μm, 200 A Magic C18 AQ matrix (Michrom Bioresources, USA) followed by separation on a 10 cm long (75 μm internal diameter) separation column that was packed with
the same matrix, MK-2206 supplier directly on a self-pack 15 μm PicoFrit empty column (New Objective, USA). Chromatography was carried out on an EASY-nLC II instrument (Thermo Scientific, USA). Samples were loaded onto the trap column at 2000 nL/min while chromatographic separation occurred at 200 nL/min. Mobile phase A consisted of 0.1% (v/v) formic acid in water while mobile phase B consisted of 0.1% (v/v) formic acid in acetonitrile and gradient conditions were as follows: 2–40% B in 32 min; up to 80% B in
4 min, maintaining at this concentration for 2 min more, before column reequilibration. Eluted peptides were directly introduced to an LTQ XL/Orbitrap mass spectrometer (Thermo, USA) for analysis. For each spectra, selleck kinase inhibitor the 10 most intense ions were submitted to CID fragmentation followed by MS2 acquisition on the linear trap analyzer. Uninterpreted tandem mass spectra were searched against the no redundant protein sequence database from the National Center for Biotechnology Information (NCBI) using the Peaks Client 5.3 build 20110708. The search parameters were as follows: metazoan taxon, no restriction of protein molecular weight, two missed trypsin cleavage allowed, non-fixed modifications of methionine (oxidation) and cysteine (carbamidomethylation) with no other post-translational modifications being taken into account. Mass tolerance for the peptides in the searches was 10 ppm for MS spectra and 0.6 Da for MS/MS.
Four examples of optimal wavelength relationships, one for each b
Four examples of optimal wavelength relationships, one for each biogeochemical quantity, are given in Table 2. In the case of SPM and POC estimates, the best results are achieved when values of bbp are used this website for the wavelength 420 nm (see lines 1 and 2 in Table 2). But the statistical parameters
characterising these two new relationships are very similar to those given for the two formulas presented earlier ( (1) and (2)) which make use of approximated values of bbp(443). No significant improvement is achieved in these two cases (compare the statistical parameters shown in Table 2 and Table 1). A small but noticeable improvement can be found for the statistical relationship between POC and an(488) (see line 3 in Table 2, and Figure 5a): equation(6) POC=1.35(an(488))0.923.POC=1.35an4880.923. In this case, when we compare it to the equation (3) selleck compound presented earlier, there is a decrease in the standard error factor X from 1.59 to 1.55. But the largest possible improvement in favour of a formula making use of the optimal wavelength is obtainable (and this is also in agreement with common physical intuition) for a formula for estimating Chl a based on values of an(676), i.e. values at the red peak of that pigment absorption spectrum (see line 4 in Table 2, and Figure 5b): equation(7) Chla=45.6an6760.854.
In this case, when we compare the standard error factor X to equation (4) presented earlier, the improvement in its value is the largest (i.e. the value of X decreases from 1.54 to 1.35). But the values of all the statistical parameters obtained in that particular case have to be treated with extra caution. The values of coefficient an(676) measured with the AC-9 instrument are spectrally located close to the 715 nm band, at which, according to the absorption measurement correction Dapagliflozin methodology applied in this work (the so-called proportional method, see the Methods section), the whole of the measured signal was assumed to have been caused by light scattering, and was consequently
subtracted to make an(715) equal to 0. Although this methodology has been widely used by many oceanographers, it is known to be an imperfect simplification (see e.g. the discussion in the paper by McKee et al. (2008)). In situations where the assumption that absorption by particles in water of the 715 nm band is negligible does not hold, the resultant corrected absorption coefficients an could be encumbered with a certain error, especially for bands lying spectrally close to the band used for correction. As a result of this, the corrected values of an(676) in our case may represent the height of the 676 nm absorption peak above the true but unknown value of absorption at 715 nm rather than the real absolute value of absorption at 676 nm. The other fact which should also be taken into account, and is obviously not analysed here, is that apart from the supposed statistical attractiveness of the Chl a vs.
Firstly, a representative Et value was obtained for each tissue b
Firstly, a representative Et value was obtained for each tissue by calculating the mean post-contrast Et (Etave) across the entire 30-min
imaging period from the group of patients with low overall Fazekas rating (<1.5). For each tissue, mean enhancement Etave was converted into contrast agent concentration Ctave, with T10 taken as the mean pre-contrast value in each tissue measured from all low Fazekas-rated patients and r1 (r2) assumed to be 4.3 (5.2) s−1 mM−1 in all tissues [30]. The variation in T10 or r1 required to produce the Etdiff observed between the low- and high Fazekas-rated patients in each tissue (see Table 1) was then calculated, Target Selective Inhibitor Library assuming the concentration Ctave remained fixed in each tissue. This procedure estimates the Selleckchem AZD4547 T10 or r1 change that would be required to cause the mean enhancement difference observed in subtle BBB breakdown due to white matter abnormalities, assuming that there is no difference in the contrast agent concentration between the two patient groups. A more generic analysis of the effects of T10, r1 and r2 on measurements of contrast agent concentration can be found in Schabel and Parker [19]. This error analysis also enables calculation of the relative uncertainty in the estimation of contrast agent concentration ɛrel when
varying experimental parameters such as SNR, flip angle αb and the number of baseline images Nb. The effect of varying these parameters was investigated for the relevant concentration range associated with subtle BBB disorders. The relationship was explored for T10 and T20⁎
parameters representative of blood, gray matter, white matter and CSF, while the effect of varying flip angle αb, number of post contrast measurements N and number of baseline measurements Nb was explored for white matter. Fig. 1 illustrates the average temporal evolution of Et triclocarban and Ct obtained from the 60 stroke patients (mean±S.D. age: 67±12 years; time from stroke onset: 68±36 days), 32 with low Fazekas rating and 28 with high rating, and Table 1 summarizes Etave and Ctave measurements for each tissue. As expected, the blood signal enhances the most with Etave≈1.5, which is approximately 20 times greater than either cortical gray matter (Etave≈0.08) or deep gray matter (Etave≈0.07). White matter enhances the least with Etave≈0.02, and CSF enhances by about double that of gray matter with Etave≈0.15. The relationship between tissues is noticeably altered when contrast agent concentration is considered. In this case, blood signal again has the highest estimated concentration with Ctave≈0.8 mM, which is roughly 40 times greater than cortical or deep gray matter which both have Ctave≈0.
For example, sunbathing/relaxing is a calming activity and, as it
For example, sunbathing/relaxing is a calming activity and, as it typically involves little movement, there would be less trampling, fewer depreciative rock pooling behaviours and less overall disturbance to the wildlife. As shown in Fig. 2, some activities (including walking and rock pooling) were beneficial to the visitor but have the potential to be rather harmful to the environment. In psychological
terms, these activities allow exploration of this environment, show fascination towards the landscape and wildlife, and may involve learning by finding certain species, or include exercise along a scenic environment (Kaplan, 1995). Environmentally, as these activities are exploratory they may involve walking over vulnerable areas and can involve depreciative behaviours such as turning rocks over and removing organisms. The activities Erlotinib ic50 seen to be damaging to the environment and not that beneficial to the visitor (including GSK3 inhibitor fishing and bait collecting) are typically associated with the resource and less focussed on a recreational purpose. Consequently, these more resource focussed activities appear to be detrimental to the environment and
not that valuable to visitors' wellbeing. This paper adopted a novel approach to explore these trade-offs; however, more research is necessary to investigate these complicated relationships and to conclude the optimum activities to encourage, while discouraging others. For example, health benefits may be higher for activities that involve more exploration of rocky shores (e.g. rock
pooling) compared to more passive activities such as sunbathing/relaxing. We focussed on psychological health effects (e.g. changes in mood, happiness) 2-hydroxyphytanoyl-CoA lyase rather than physiological health implications. Future research would be well placed to investigate such additional trade-offs. With our paper we hope to begin a discussion around more integrative approaches that appreciate the complexity of the overall impacts (on both visitors and the environment), with the end goal of informing management practices accordingly. It was noted that this research only assessed participants' perceptions and not actual experiences. This perceptual approach is both a strength and a weakness. For visitor impacts, we could have recorded actual visitors' experiences via self-report questionnaires and/or physiological measures. Similarly, for the environmental impacts, objective frequency data could have been collected and/or a more experimental approach could have been used, such as examining the effects visits have on rocky shores by manipulating intensity and types of activities and recording their impacts on different organisms. However, as there has been little research examining both components together, it would have been premature to do this.
In other words, if there is a single effector
Cancer Lett 2009, 276:189–195 PubMedCrossRef Competing interests
1 0%, 69/119) presented a prolonged PFS (4 2 months vs 1 2 month
The 29-and 27-kDa proteins were mainly detected in the cytoplasm/
Laparoscopic management of small bowel perforations was reported
jak-inhibitors